See more : International Games System Co.,Ltd. (3293.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Medicine (MindMed) Inc. (MNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Leoch International Technology Limited (LCHIF) Income Statement Analysis – Financial Results
- Financial 15 Split Corp. (FTN.TO) Income Statement Analysis – Financial Results
- Kakiyasu Honten Co., Ltd. (2294.T) Income Statement Analysis – Financial Results
- LEVERAGE SHARES PUBLIC LIMITED (1ARW.L) Income Statement Analysis – Financial Results
- Cipher Pharmaceuticals Inc. (CPH.TO) Income Statement Analysis – Financial Results
Mind Medicine (MindMed) Inc. (MNMD)
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.16M | 3.22M | 2.62M | 0.00 | 6.68K | 6.68K | 5.50K | 0.00 | 0.00 |
| Gross Profit | -3.16M | -3.22M | -2.62M | 0.00 | -6.68K | -6.68K | -5.50K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.96M | 36.17M | 34.79M | 18.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 41.74M | 30.16M | 59.07M | 14.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.74M | 30.16M | 59.07M | 14.40M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Other Expenses | 0.00 | 2.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Cost & Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 468.18K | 861.94K | 1.24M | 111.25K | 94.55K |
| Interest Income | 4.66M | 1.50M | 0.00 | 0.00 | 0.00 | 4.00K | 8.40K | 1.20K | 1.90K |
| Interest Expense | 0.00 | 1.50M | 359.00K | 164.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.16M | 3.22M | 2.62M | 206.30K | 6.68K | 6.68K | 5.50K | 0.00 | 0.39 |
| EBITDA | -92.57M | -53.57M | -91.22M | -33.77M | -1.11M | -851.26K | -1.51M | -111.25K | -92.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.87M | -66.33M | -96.36M | -33.03M | -468.18K | -861.94K | -1.24M | -111.25K | -94.55K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.87M | 9.54M | -339.00K | -907.00K | -647.63K | 4.00K | 8.40K | -68.65K | 1.89K |
| Income Before Tax | -95.73M | -56.80M | -94.19M | -33.94M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -9.54M | -1.16M | 164.00K | -3.69 | -1.91 | -1.70 | 0.00 | -0.39 |
| Net Income | -95.73M | -47.26M | -93.04M | -34.10M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| EPS Diluted | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| Weighted Avg Shares Out | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
| Weighted Avg Shares Out (Dil) | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase...
MindMed to Present at Upcoming April Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact...
MindMed Announces Voluntary Delisting from Cboe Canada
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its...
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will...
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
VANCOUVER, BC , March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, congratulates...
Psychedelics stocks fly as FDA recognizes Mind Medicine's LSD drug as breakthrough therapy
Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the news that MindMed (NASDAQ:MNMD, NEO:MMED)'s LSD drug candidate was granted breakthrough therapy status by the US Food and Drug Administration (FDA) for the treatment of generalized...
Why Is MindMed (MNMD) Stock Up 32% Today?
MindMed (NASDAQ: MNMD ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company received breakthrough therapy designation from the Food and Drug Administration (FDA). This designation covers the company's MM120 program in development to treat generalized anxiety disorder.
Mind Medicine's LSD drug candidate awarded FDA breakthrough therapy designation; shares soar
MindMed (NASDAQ:MNMD, NEO:MMED) shares soared more than 26% higher before Thursday's opening bell after the biopharmaceutical firm revealed that its drug candidate MM120 has been awarded breakthrough therapy status from the US Food and Drug Administration (FDA) for the treatment...
Source: https://incomestatements.info
Category: Stock Reports